This article has been updated from a previous version to include comments made during Fluidigm's earnings call.

NEW YORK (GenomeWeb) – Fluidigm said Thursday after the close of the market that its first quarter revenues decreased 12 percent year over year.

For the three months ended March 31, the South San Francisco, California-based single-cell biology firm brought in revenues of $25.5 million compared to $29.0 million in the first quarter of 2016. Total revenues edged out the consensus Wall Street estimate of $25.0 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Sponsored by

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.